Therapeutic antibodies targeting immune checkpoint molecules, such as programmed cell death 1 (PD-1) and its ligand PD-ligand 1 (PD-L1), have shown great promise in cancer treatment, by reinvigorating immune responses against cancers1. Here, CD274 is linked to cancer.